The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Year to date metric has recorded a gain of 59.81%.However, over the last six months, we can see a weaker performance of 41.84%. Over the last 30 days, the price of XFOR has fallen by 59.18%. And in the last five days, it has fallen by -2.19%.
In terms of market performance, X4 Pharmaceuticals Inc had a fairly even. The highest value for the stock in the past year was $2.58 on 06/13/23, and the lowest value was recorded at $0.57 on 12/12/23.
52-week price history of XFOR Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. X4 Pharmaceuticals Inc’s current trading price is -47.96% away from its 52-week high, while its distance from the 52-week low is 134.14%. The stock’s price range during this time has been between $0.57 and $2.58. The trading volume for the Healthcare sector company’s shares reached about 5.64 million for the day, which was higher than the average daily volume of 2.22 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
X4 Pharmaceuticals Inc (XFOR) has experienced a quarterly rise of 59.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 225.04M and boasts a workforce of 93 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9247, with a change in price of +0.5743. Similarly, X4 Pharmaceuticals Inc recorded 2,391,166 in trading volume during the last 100 days, posting a change of +75.00%.
XFOR’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for XFOR stands at 1.14. Similarly, the long-term debt-to-equity ratio is also 1.12.
XFOR Stock Stochastic Average
Today, X4 Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 68.64%, indicating a rise from the raw stochastic average of the last 20 days, which was 65.54%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 56.68% and 55.72% respectively.
